Top Pharmaceutical Companies in USA List by Market Cap as on July-30-2023

Bio-pharmaceutical company with headquarters is in California, USA.

Acadia Pharmaceuticals is a Healthcare and Pharmaceutical company. The company is of food and drug administration for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Around 8 million people in the United States are living with dementia and studies suggest that approximately 30% of people with dementia, 2.4 million people, experience dementia-related hallucinations and delusion. The headquarters is in USA.

Bio-pharmaceutical company with headquarters is in Massachusetts, USA.

Madrigal Pharmaceuticals is a Clinical Stage Biopharmaceutical company. It is pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver which is a key regulatory mechanism common to a spectrum of cardio metabolic and fatty liver diseases with high unmet medical need. The headquarters is in USA.

Bio-pharmaceutical company with headquarters is in California, USA.

Apellis Pharmaceuticals is a Biopharmaceutical company that is committed to leveraging courageous science, creativity and compassion to deliver life changing therapies. The company develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade including those within hematology, ophthalmology, nephrology and neurology. The headquarters is in USA.

Ultragenyx Pharmaceutical is a Clinical Stage Biopharmaceutical company. It committed to bringing to patients novel products for the treatment of rare and ultra rare diseases with a focus on serious debilitating genetic diseases. The company portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for which there are no approved therapies. The headquarters is in USA.

Momenta Pharmaceuticals is a Biotechnology company. The headquarters is in USA.

Johnson & Johnson acquired Momenta Pharmaceuticals as on Oct-2020 for 6.5 Billion USD.

Portola Pharmaceuticals is a Biotechnology company. It is having more than 380 employees and has offices around the globe and serves patients in more than 50 countries. The company has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome (aHUS) as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder.